Immunovant (IMVT) Operating Expenses (2018 - 2026)
Immunovant's (IMVT) quarterly Operating Expenses came in at $159.6 million in Q1 2026, up 40.17% YoY from $113.8 million in Q1 2025, and up 39.52% on a QoQ basis from $114.4 million in Q4 2025.
Immunovant (IMVT) Operating Expenses (2018 - 2026) Analysis & Trends
Immunovant (IMVT) has 9 years of Operating Expenses data on file, last reported at $159.6 million in Q1 2026.
- Quarterly Operating Expenses rose 40.17% year-over-year to $159.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $532.9 million (up 21.63% YoY) and the FY2026 annual result came in at $532.9 million, up 21.62% from the prior year.
- Operating Expenses advanced to $159.6 million in Q1 2026, from $114.4 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $159.6 million in Q1 2026 to a low of $40.4 million in Q2 2022.
- A 5-year average of $89.4 million and a median of $80.9 million in 2024 frame the typical range for Operating Expenses.
- The widest YoY moves for Operating Expenses: up 94.37% in 2023, down 3.86% in 2023.
- Tracing IMVT's Operating Expenses over 5 years: stood at $64.0 million in 2022, then slipped by 3.86% to $61.6 million in 2023, then jumped by 85.7% to $114.3 million in 2024, then increased by 0.05% to $114.4 million in 2025, then jumped by 39.52% to $159.6 million in 2026.
- The last three Operating Expenses figures came in at $159.6 million (Q1 2026), $114.4 million (Q4 2025), and $131.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - | 160.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 160.32 Mn |
| Mar 31, 2026 | 159.55 Mn |
| Dec 31, 2025 | 114.36 Mn |
| Sep 30, 2025 | 131.76 Mn |
| Jun 30, 2025 | 127.22 Mn |
| Mar 31, 2025 | 113.83 Mn |
| Dec 31, 2024 | 114.30 Mn |
| Sep 30, 2024 | 115.74 Mn |
| Jun 30, 2024 | 94.28 Mn |
| Mar 31, 2024 | 80.88 Mn |
| Dec 31, 2023 | 61.55 Mn |
| Sep 30, 2023 | 61.80 Mn |
| Jun 30, 2023 | 78.48 Mn |
| Mar 31, 2023 | 64.26 Mn |
| Dec 31, 2022 | 64.03 Mn |
| Sep 30, 2022 | 49.61 Mn |
| Jun 30, 2022 | 40.38 Mn |
| Mar 31, 2022 | 47.23 Mn |
| Dec 31, 2021 | 41.27 Mn |
| Sep 30, 2021 | 37.65 Mn |